7Baggers

Assembly Biosciences, Inc
(NASDAQ:ASMB) 

ASMB stock logo

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H21...

Founded: 2005
Full Time Employees: 140
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 
                                                                 
      collaboration revenue from a related party
    		42,469,000 10,789,000 9,626,000 9,419,000 5,290,750 6,845,000 8,533,000 5,785,000                                                      
      operating expenses
    		                                                             
      research and development
    		17,250,000 16,587,000 16,125,000 14,851,000 14,280,000 13,515,000 16,259,000 11,879,000 11,006,000 10,824,000 12,523,000 14,547,000 16,853,000 18,130,000 17,792,000 17,205,000 14,747,000 18,474,000 16,749,000 18,554,000 33,509,000 26,941,000 23,327,000 23,046,000 22,616,000 21,736,000 18,700,000 22,704,000 21,250,780 19,108,918 17,840,128 14,541,174 10,596,825 10,929,436 12,125,021 10,573,739 8,622,343 8,833,027 7,519,031 8,118,576 5,225,601 4,630,148 4,667,754 3,834,434 2,975,420 3,671,983 1,095,644 2,973,690 5,158,207 3,753,319 3,508,450 2,609,103 2,741,386 4,188,127 6,161,924 6,422,726  3,667,179 3,099,582 970,762  
      general and administrative
    		5,420,000 5,085,000 4,594,000 4,509,000 4,609,000 4,286,000 4,477,000 4,635,000 8,708,000 4,224,000 4,965,000 5,012,000 6,125,000 5,271,000 6,781,000 5,957,000 6,504,000 6,655,000 6,917,000 8,704,000 7,170,000 11,689,000 9,470,000 8,729,000 10,834,000 8,488,000 4,080,000 9,517,000 8,805,814 7,752,493 12,543,658 5,696,035 4,998,250 4,180,357 3,801,541 4,040,459 3,245,911 2,845,898 2,935,099 3,158,576 2,950,680 2,492,078 2,486,151 3,368,784 3,309,297 7,383,457 1,410,500 1,136,461 935,838 1,179,689 1,300,309 1,159,865 1,075,444 1,182,176 1,316,382 1,767,331  1,878,718 3,801,989 1,696,030  
      total operating expenses
    		22,670,000 21,672,000 20,719,000 19,360,000 18,889,000 17,801,000 20,736,000 16,514,000 19,714,000 15,048,000 17,488,000 19,559,000 22,978,000 23,401,000 24,573,000 23,162,000 62,889,000 25,129,000 23,666,000 27,258,000 40,679,000 38,630,000 32,797,000 31,775,000 33,450,000 30,224,000 22,780,000 32,221,000 30,056,594 26,861,411 30,383,786 20,237,209 15,595,075 15,109,793 15,926,562 14,614,198 11,868,254 11,678,925 10,454,130 11,277,152 8,176,281 7,122,226 7,153,905                   
      income from operations
    		19,799,000 -10,883,000 -11,093,000 -9,941,000 -11,532,000 -10,956,000 -12,203,000 -10,729,000 -12,551,000 -15,048,000 -17,488,000 -19,559,000 -22,978,000 -23,401,000 -24,573,000 -23,162,000 -62,889,000 -18,875,000 -23,666,000 -27,258,000 -39,642,000 -4,019,000 6,579,000 -27,694,000 -28,684,000 -25,993,000 -19,700,000 -28,336,000 -26,321,367 -22,575,563 -27,165,921 -16,672,149 -12,279,618 -12,450,180 -13,567,251 -13,929,829 -11,868,254 -11,678,925 -10,454,130 -11,277,152 -8,176,281 -7,122,226 -7,153,905 -7,203,218 -6,284,717 -11,055,440 -2,506,144 -4,110,151 -6,094,045 -4,933,008 -4,808,759 -3,768,968 -3,816,830 -5,370,303 -7,478,306 -8,190,057  -5,545,897 -6,901,571 -2,666,792  
      yoy
    		-271.69% -0.67% -9.10% -7.34% -8.12% -27.19% -30.22% -45.15% -45.38% -35.70% -28.83% -15.56% -63.46% 23.98% 3.83% -15.03% 58.64% 369.64% -459.72% -1.57% 38.20% -84.54% -133.40% -2.27% 8.98% 15.14% -27.48% 69.96% 114.35% 81.33% 100.23% 19.69% 3.47% 6.60% 29.78% 23.52% 45.15% 63.98% 46.13% 56.56% 30.10% -35.58% 185.45% 75.25% 3.13% 124.11% -47.88% 9.05% 59.66% -8.14% -35.70% -53.98%  -3.17% 8.36% 207.11%      
      qoq
    		-281.93% -1.89% 11.59% -13.80% 5.26% -10.22% 13.74% -14.52% -16.59% -13.95% -10.59% -14.88% -1.81% -4.77% 6.09% -63.17% 233.19% -20.24% -13.18% -31.24% 886.36% -161.09% -123.76% -3.45% 10.35% 31.94% -30.48% 7.65% 16.59% -16.90% 62.94% 35.77% -1.37% -8.23% -2.60% 17.37% 1.62% 11.72% -7.30% 37.93% 14.80% -0.44% -0.68% 14.61% -43.15% 341.13% -39.03% -32.55% 23.54% 2.58% 27.59% -1.25% -28.93% -28.19% -8.69%   -19.64% 158.80%   
      other income
    		                          4,000 1,000                                  
      interest and other income
    		2,291,000 1,687,000 895,000 1,123,000 1,121,000 1,343,000 1,457,000 1,652,000 1,622,000 628,000 592,000 609,000 583,000 256,000 112,000 71,000 101,000 72,000 71,000 58,000 224,000 670,000 691,000 1,039,000 859,000 983,000 1,182,000 1,276,000 1,067,525 1,116,053 453,016 446,406 365,541 241,326 239,858 136,484 225,681 378,381 444,605 490,421 456,647 502,684 211,234                   
      total other income
    		2,291,000 1,687,000 895,000 1,123,000 1,121,000 1,343,000 1,457,000 1,652,000 1,622,000 628,000 592,000 609,000 583,000 256,000 112,000 71,000 101,000 72,000 71,000 58,000 224,000 670,000 691,000 1,039,000 859,000 983,000 1,186,000 1,277,000 1,299,845 1,033,983 325,782 423,390 327,713 142,258 -101,126 -764 -296,105 104,808 301,930 288,594 428,005 504,293 211,234 58,265 55,366 35,182                
      income before income taxes
    		22,090,000 -9,196,000 -10,198,000  -10,411,000 -9,613,000 -10,746,000              -39,418,000 -3,349,000 7,270,000 -26,655,000 -27,825,000 -25,010,000 -18,514,000 -27,059,000 -25,021,522 -21,541,580 -26,840,139  -11,951,905 -12,307,922 -13,668,377                           
      income tax expense
    		    -76,000  406,000                                                       
      net income
    		22,090,000 -9,196,000 -10,198,000 -8,818,000 -10,335,000 -9,613,000 -11,152,000 -9,077,000 -10,962,000 -14,420,000 -16,896,000 -18,950,000 -22,395,000 -23,145,000 -24,461,000 -23,091,000 -60,257,000 -18,803,000 -23,595,000 -27,200,000 -39,418,000 -3,349,000 7,270,000 -26,655,000 -27,084,000 -24,995,000 -18,503,000 -27,052,000 -26,160,971 -21,535,038 -26,806,232 -16,248,759 -3,007,072 -12,272,019 -13,598,864 -13,930,593 -11,546,687 -11,574,117 -10,152,200 -10,988,558 -7,748,276 -6,617,933 -6,942,671 -7,144,953 -6,229,351 -11,020,258 -2,469,273 -4,069,917 -6,047,034 -4,881,742 -4,751,888 -3,723,095 -3,791,109 -5,355,397 -7,470,048 -8,173,876  -5,801,381 -6,961,511 -2,722,478  
      yoy
    		-313.74% -4.34% -8.55% -2.85% -5.72% -33.34% -34.00% -52.10% -51.05% -37.70% -30.93% -17.93% -62.83% 23.09% 3.67% -15.11% 52.87% 461.45% -424.55% 2.04% 45.54% -86.60% -139.29% -1.47% 3.53% 16.07% -30.98% 66.49% 769.98% 75.48% 97.12% 16.64% -73.96% 6.03% 33.95% 26.77% 49.02% 74.89% 46.23% 53.79% 24.38% -39.95% 181.16% 75.56% 3.01% 125.74% -48.04% 9.32% 59.51% -8.84% -36.39% -54.45%  -7.69% 7.30% 200.24%      
      qoq
    		-340.21% -9.83% 15.65% -14.68% 7.51% -13.80% 22.86% -17.20% -23.98% -14.65% -10.84% -15.38% -3.24% -5.38% 5.93% -61.68% 220.46% -20.31% -13.25% -31.00% 1077.01% -146.07% -127.27% -1.58% 8.36% 35.09% -31.60% 3.41% 21.48% -19.66% 64.97% 440.35% -75.50% -9.76% -2.38% 20.65% -0.24% 14.01% -7.61% 41.82% 17.08% -4.68% -2.83% 14.70% -43.47% 346.30% -39.33% -32.70% 23.87% 2.73% 27.63% -1.79% -29.21% -28.31% -8.61%   -16.66% 155.70%   
      other comprehensive loss
    		                                                             
      unrealized gain on marketable securities
    		49,000 189,000   -55,000 137,000 -54,000 -158,000 194,000 50,000 188,000 290,000     -4,500 -15,000 -2,000 -1,000                    72,090                      
      comprehensive loss
    		22,139,000 -9,007,000 -10,224,000 -8,860,000 -10,390,000 -9,476,000 -11,206,000 -9,235,000 -10,768,000 -14,370,000 -16,708,000 -18,660,000 -22,199,000 -23,146,000 -24,551,000 -23,580,000 -60,388,000 -18,818,000  -27,201,000 -39,530,000 -3,611,000  -26,540,000 -27,080,000 -25,013,000 -18,451,000 -26,944,000 -26,153,466 -21,517,856 -26,718,960 -16,315,718 -3,011,074 -12,262,141 -13,472,454 -13,854,501 -11,310,888 -11,571,323 -10,242,067 -10,916,468 -8,181,983 -6,871,592 -7,076,890                   
      net income per share
    		2.48 -0.72 -1.33 -1.17 -1.57 -1.51 -1.98 -1.66 -12.41 -0.27 -0.32 -0.37 -0.46 -0.48 -0.51 -0.48 -1.37 -0.41 -0.55 -0.69 -1.11 -0.09 0.21 -0.76 -0.98 -0.96 -0.72 -1.05 -1.03 -0.87 -1.3 -0.8 -0.11 -0.71 -0.78 -0.81 -0.67 -0.67 -0.59 -0.64 -0.45 -0.38 -0.41 -0.64 -0.38 -1.33                
      weighted-average common shares outstanding, basic and diluted
    		11,210,934 12,686,122 7,655,854 7,506,321 6,004,560 6,351,431 5,642,752 5,483,313 4,577,371 52,565,333 52,260,088 51,012,450 48,409,265 48,448,399 48,293,495 48,123,930 43,280,383 45,569,276  39,679,734 35,427,120 35,506,042  35,079,756 26,258,790 25,912,568 25,740,500 25,668,798 22,801,644 24,878,413 20,541,549 20,231,804 17,750,380 17,367,523 17,342,623 17,268,280 17,226,245 17,225,554 17,225,660 17,225,662 15,702,646 17,205,863 17,119,488 11,176,580 6,998,875 8,277,355                
      unrealized loss on marketable securities
    		  26,000 42,000         196,000 -1,000 -90,000 -489,000                         -433,707 -253,659 -134,219                   
      collaboration revenue
    		                 6,254,000   1,037,000 34,611,000 39,376,000 4,081,000 4,766,000 4,231,000 3,080,000 3,885,000 3,735,227 4,285,848 3,217,865 3,565,060 3,315,457 2,659,613 2,359,311 684,369                          
      operating expenses:
    		                                                             
      other income:
    		                                                             
      other comprehensive income
    		                                                             
      comprehensive income
    		                  -23,597,000    7,460,000                                       
      weighted-average common shares outstanding, basic
    		                  42,876,268    35,307,669                                       
      weighted-average common shares outstanding, diluted
    		                  42,876,268    37,291,474                                       
      income tax benefit
    		                        741,000 15,000 11,000 7,000 10,112.25 6,542 33,907  8,944,833 35,903 69,513                           
      unrealized gain on marketable securities, net of tax
    		                    -112,000 -262,000 190,000 115,000 4,000 -18,000 52,000 108,000                                  
      realized loss from marketable securities
    		                            -58,080 -82,070 -127,234 -23,016 -37,828 -99,068 -340,984 -137,248 -521,786 -273,573 -142,675 -201,827                      
      unrealized loss recognized in accumulated other comprehensive loss before reclassification, net of tax benefit of 50,664, 31,844, 44,192 and 89,281, respectively
    		                            -34,671.5 -8,749                                
      reclassification adjustment of unrealized loss included in net loss, net of tax expense of 56,139, 37,987, 56,139 and 221,358, respectively
    		                            44,045.25 25,931                                
      unrealized loss recognized in accumulated other comprehensive loss before reclassification, net of tax benefit of 29,835, 57,437, 29,835 and 57,437, respectively
    		                              -39,962                               
      reclassification adjustment of unrealized loss included in net loss, net of tax expense of 36,307, 183,371, 36,307 and 183,371, respectively
    		                              127,234                               
      unrealized loss recognized in accumulated other comprehensive loss before reclassification
    		                               -89,975    -61,156 -158,264.5 -270,779 -232,542                       
      reclassification adjustment of unrealized loss included in net loss
    		                               23,016    137,248 154,518.75 273,573 142,675                       
      unrealized loss recognized in accumulated other comprehensive loss before reclassification, net of tax benefit of 31,844, 0, 89,281 and 0, respectively
    		                                -35,890.5 -51,203                            
      reclassification adjustment of unrealized loss included in net loss, net of tax expense of 37,987, 0, 221,358 and 0, respectively
    		                                88,985.5 61,081                            
      unrealized loss recognized in accumulated other comprehensive loss before reclassification, net of tax benefit of 57,437, 0, 57,437 and 0, respectively
    		                                  -31,203                           
      reclassification adjustment of unrealized loss included in net loss, net of tax expense of 183,371, 0, 183,371 and 0, respectively
    		                                  157,613                           
      realized gain from marketable securities
    		                                        402.25 1,609                    
      total operating costs and expenses
    		                                           7,203,218 6,284,717 11,055,440                
      interest income
    		                                           58,265 55,366 35,182 36,871 40,234 47,011 51,266 56,871 45,873 25,721 14,906 8,258 16,181  28,423 5,967 13,490  
      basic and diluted net loss per common share
    		                                              -0.52 -0.18 -0.29 -0.25 -0.24 -0.22 -0.28 -0.41 -0.59 -0.66  -0.5 -0.97 -0.38  
      weighted-average common shares outstanding - basic and diluted
    		                                              4,704,251 22,094,700 19,393,486 19,894,525   12,726,551       7,147,624  
      interest expense:
    		                                                             
      beneficial conversion feature
    		                                                             
      amortization of debt discount and warrants
    		                                                         -253,302 -24,512   
      interest expense
    		                                                         -30,605 -41,395 -44,663  
      weighted-average common shares outstanding – basic and diluted
    		                                                  19,722,482 17,055,572   12,627,316 12,408,927 9,613,900 11,616,786 7,176,491   
      weighted average common shares outstanding – basic and diluted
    		                                                     12,933,340        
      interest expense: - sum
    		                                                         -283,907 -65,907 -69,176  
      amortization of debt discount and deferred financing costs
    		                                                           -24,513  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2013-09-30 2011-09-30 2011-06-30 2011-03-31 2010-12-31 
                                                          
        assets
      		                                                    
        current assets
      		                                                    
        cash and cash equivalents
      		58,450,000 22,534,000 24,006,000 23,413,000 38,344,000 28,452,000 19,208,000 18,749,000 19,841,000 26,656,000 21,623,000 43,482,000 52,418,000 54,673,000 43,063,000 51,174,000 45,627,000 70,760,000 59,517,000 78,253,000 59,444,000 58,311,000 96,709,000 42,326,000 46,732,000 24,867,000 34,258,000 29,107,000 41,471,000 119,752,339 54,192,131 66,926,630 82,033,209 27,247,232 39,452,737 70,818,011 28,575,085 23,794,088 20,341,338 20,395,045 27,107,526 36,401,487 53,518,145   17,932,627 21,316,328 32,222,910 53,294,262 11,368,535 14,000,524  
        marketable securities
      		189,656,000 210,023,000 50,974,000 67,615,000 73,735,000 66,502,000 90,011,000 94,227,000 110,406,000 19,554,000 38,208,000 29,534,000       139,560,000 136,631,000 156,969,000 179,630,000 130,005,000 206,803,000 227,311,000 132,070,000 139,553,000 164,429,000             23,392,129 29,396,382 17,209,448          
        accounts receivable from collaboration with a related party
      		974,000 912,000                                                   
        prepaid expenses and other current assets
      		5,469,000 3,343,000 2,487,000 4,499,000 3,424,000 3,259,000 3,712,000 4,149,000 3,497,000 3,462,000 3,908,000 6,011,000 4,413,000 5,181,000 7,082,000 7,253,000 7,241,000 6,548,000 6,184,000 6,547,000 6,850,000 4,856,000 5,059,000 4,568,000 5,363,000 5,441,000 6,746,000 4,283,000 1,992,000 3,342,759 2,731,385 1,803,066 897,400 951,334 978,356 1,298,673 611,176                
        total current assets
      		254,549,000 236,812,000 77,467,000 95,527,000 115,503,000 98,213,000 112,931,000 117,168,000 133,787,000 49,672,000 64,081,000 79,744,000 96,967,000 115,078,000 124,294,000 130,777,000 154,204,000 188,219,000 205,558,000 221,634,000 224,493,000 246,387,000 235,088,000 256,752,000 282,780,000 165,322,000 183,460,000 200,806,000 222,502,000 239,872,753 97,529,218 113,225,600 123,118,512 68,651,761 77,668,536 92,221,684 53,574,664 59,254,826 64,102,987 59,089,199 68,368,465 66,503,164 71,332,755 96,337,918 29,216,397 18,079,805 21,747,803 32,357,690 53,379,245 11,465,642 14,102,055 14,589,970 
        property and equipment
      		221,000 229,000 219,000 251,000 284,000 316,000 349,000 367,000 385,000 561,000 541,000 619,000 743,000 867,000 899,000 1,019,000 1,139,000 1,241,000 1,359,000 1,493,000 1,600,000 1,904,000 2,063,000 1,780,000 1,830,000 1,931,000 2,048,000 2,079,000                         
        operating lease right-of-use (rou) assets
      		2,508,000 2,644,000 2,782,000 2,927,000 3,069,000 1,421,000 1,731,000 2,036,000 2,339,000 844,000 1,623,000 2,419,000 3,195,000 3,958,000 4,711,000 5,300,000 6,042,000 6,773,000 7,488,000 8,104,000 9,131,000 10,397,000 10,780,000 11,479,000                             
        other assets
      		312,000 312,000 312,000 312,000 312,000 312,000 312,000 312,000 312,000 552,000 332,000 334,000 889,000 1,613,000 1,635,000 2,175,000 1,703,000 1,922,000 6,093,000 6,034,000 6,392,000 5,980,000 5,232,000 1,661,000 1,684,000 1,671,000 1,693,000 1,661,000 3,348,000                        
        total assets
      		257,590,000 239,997,000 80,780,000 99,017,000 119,168,000 100,262,000 115,323,000 119,883,000 136,823,000 51,629,000 66,577,000 83,116,000 101,794,000 121,516,000 143,447,000 162,730,000 191,060,000 248,973,000 262,136,000 278,903,000 283,254,000 306,306,000 294,801,000 313,310,000 339,907,000 223,345,000 241,511,000 259,247,000 268,045,000 282,977,202 142,418,089 156,020,828 169,303,445 112,313,122 122,774,619 134,284,191 98,118,606 109,127,019 117,205,921 124,454,324 133,744,497 139,654,016 144,707,127 138,347,415 71,225,193 60,393,941 21,755,202 32,365,322 53,388,460 11,523,832 14,137,821 14,616,601 
        liabilities and stockholders' equity
      		                                                    
        current liabilities
      		                                                    
        accounts payable
      		1,171,000 1,683,000 743,000 875,000 585,000 1,335,000 801,000 727,000 461,000 758,000 904,000 1,224,000 2,493,000 1,942,000 2,454,000 1,407,000 2,659,000 2,628,000 2,866,000 3,562,000 4,598,000 1,611,000 3,640,000 2,104,000 1,731,000 2,709,000 3,414,000 2,427,000 3,693,000 2,987,565 2,538,976 2,372,874 2,123,939 870,607 687,908 1,947,183 2,368,131 3,837,964 2,413,922 2,326,148 1,363,698 1,464,339 1,304,295 1,250,843 907,601  1,421,353 2,280,245  621,731 122,896 312,896 
        accrued research and development expenses
      		2,387,000 3,058,000 1,691,000 2,106,000 2,273,000 1,586,000 2,531,000 2,059,000 885,000 1,619,000 2,037,000 3,046,000 3,122,000 4,462,000 4,446,000 3,596,000 3,400,000                                    
        other accrued expenses
      		7,749,000 5,728,000 3,407,000 2,302,000 6,862,000 4,765,000 3,587,000 2,051,000 5,744,000 3,886,000 4,188,000 3,154,000 7,317,000 5,686,000 4,750,000 2,499,000 6,863,000 5,457,000 4,320,000 3,659,000 11,987,000 7,404,000 6,019,000 4,430,000 8,286,000                            
        deferred revenue from a related party - short-term
      		36,904,000 42,363,000 40,917,000 40,819,000 37,622,000 32,620,000 33,060,000 32,771,000                                             
        operating lease liabilities - short-term
      		569,000 548,000 533,000 529,000 461,000 1,329,000 1,295,000 1,145,000 1,220,000 869,000 1,702,000 2,546,000 3,364,000 3,371,000 3,311,000 3,207,000 3,151,000 3,099,000 3,048,000 2,934,000 3,404,000 3,338,000 3,250,000 3,264,000 3,186,000 3,208,000 2,854,000 2,704,000                         
        total current liabilities
      		48,780,000 53,380,000 47,291,000 46,631,000 47,803,000 41,635,000 41,274,000 38,753,000 39,225,000 7,132,000 8,831,000 9,970,000 16,296,000 15,461,000 14,961,000 10,709,000 16,073,000 14,928,000 13,910,000 14,497,000 24,433,000 16,804,000 17,271,000 21,146,000 24,440,000 21,498,000 19,935,000 25,205,000 18,472,000 14,609,722 13,130,865 12,179,933 13,492,166 12,219,013 11,989,349 10,956,639 7,120,954 7,482,246 5,044,868 3,569,342 3,402,902 2,651,569 2,239,960 2,128,383 1,054,021 1,049,019 1,469,788 2,317,660 1,183,442 769,941 310,432 1,719,812 
        deferred revenue from a related party - long-term
      		 1,715,000 13,038,000 22,762,000 35,378,000 32,511,000 38,916,000 47,738,000                                             
        operating lease liabilities - long-term
      		2,059,000 2,207,000 2,351,000 2,491,000 2,628,000 113,000 451,000 791,000 1,122,000 50,000 64,000 80,000 101,000 918,000 1,773,000 2,497,000 3,325,000 4,136,000 4,914,000 5,644,000 6,725,000 7,435,000 7,884,000 8,539,000 9,082,000 9,839,000 10,035,000 10,521,000                         
        total liabilities
      		50,839,000 57,302,000 62,680,000 71,884,000 85,809,000 74,259,000 80,641,000 87,282,000 95,726,000 9,915,000 11,628,000 12,783,000 19,130,000 19,112,000 19,467,000 15,939,000 22,131,000 24,328,000 30,342,000 31,659,000 42,676,000 35,757,000 27,686,000 61,542,000 66,690,000 66,856,000 66,804,000 68,846,000 57,392,000 53,543,978 53,317,524 53,639,579 56,183,676 65,180,271 66,239,607 66,396,027 18,240,605 19,082,246 16,644,868 15,169,342 15,002,902 14,251,569 13,839,960 13,728,383 12,654,021 13,191,721   1,183,442 2,089,639 1,605,618 2,990,485 
        commitments and contingencies
      		                                                    
        stockholders' equity
      		                                                    
        preferred stock, 0.001 par value...
      		                                                    
        common stock, 0.001 par value...
      		16,000 16,000 8,000 8,000 7,000 6,000 6,000 5,000 5,000 53,000 52,000 52,000 49,000 48,000 48,000 48,000 48,000 47,000 44,000 40,000 34,000 33,000 33,000 32,000 32,000 26,000 26,000 26,000 25,000 25,460 20,614 20,387 20,138 17,386 17,361 17,318 17,247 17,226 17,226 17,226 17,226 17,226 17,190 16,251 10,672 8,688       
        additional paid-in capital
      		1,038,823,000 1,036,906,000 863,312,000 862,121,000 859,488,000 841,743,000 840,946,000 827,660,000 826,921,000 816,722,000 815,588,000 814,264,000 807,938,000 805,480,000 803,910,000 802,170,000 800,728,000 796,057,000 784,391,000 776,248,000 742,387,000 732,829,000 725,784,000 717,898,000 712,807,000 569,005,000 562,210,000 559,453,000 552,762,000 545,388,704 383,543,035 370,104,986 364,528,037 295,532,797 292,672,842 290,553,583 288,688,990 287,544,895 286,489,852 284,971,714 283,511,859 281,990,728 280,583,892 267,259,806 194,072,572 176,107,503 138,174,448 135,334,268 100,862,340 52,295,308 48,431,845 44,803,724 
        accumulated other comprehensive loss
      		-41,000 -90,000 -279,000 -253,000 -211,000 -156,000 -293,000 -239,000 -81,000 -275,000 -325,000 -513,000 -803,000 -999,000 -998,000 -908,000 -419,000 -288,000 -273,000 -271,000 -270,000 -158,000  -86,000 -201,000 -205,000 -187,000 -239,000 -347,000 -354,896 -372,078 -459,350 -392,391 -388,389 -398,267 -524,677 -600,769 -836,568 -839,362 -749,495 -821,585 -387,878 -134,219          
        accumulated deficit
      		-832,047,000 -854,137,000 -844,941,000 -834,743,000 -825,925,000 -815,590,000 -805,977,000 -794,825,000 -785,748,000 -774,786,000 -760,366,000 -743,470,000 -724,520,000 -702,125,000 -678,980,000 -654,519,000 -631,428,000 -571,171,000 -552,368,000 -528,773,000 -501,573,000 -462,155,000 -458,806,000 -466,076,000 -439,421,000 -412,337,000 -387,342,000 -368,839,000 -341,787,000 -315,626,044 -294,091,006 -267,284,774 -251,036,015 -248,028,943 -235,756,924 -222,158,060 -208,227,467 -196,680,780 -185,106,663 -174,954,463 -163,965,905 -156,217,629 -149,599,696 -142,657,025 -135,512,072 -129,282,721 -118,262,463      
        total stockholders' equity
      		206,751,000 182,695,000 18,100,000 27,133,000 33,359,000 26,003,000 34,682,000 32,601,000 41,097,000 41,714,000 54,949,000 70,333,000 82,664,000 102,404,000 123,980,000 146,791,000 168,929,000 224,645,000 231,794,000 247,244,000 240,578,000 270,549,000 267,115,000 251,768,000 273,217,000 156,489,000 174,707,000 190,401,000 210,653,000 229,433,224 89,100,565 102,381,249 113,119,769 47,132,851 56,535,012 67,888,164 79,878,001 90,044,773 100,561,053 109,284,982 118,741,595 125,402,447 130,867,167 124,619,032 58,571,172        
        total liabilities and stockholders' equity
      		257,590,000 239,997,000 80,780,000 99,017,000 119,168,000 100,262,000 115,323,000 119,883,000 136,823,000 51,629,000 66,577,000 83,116,000 101,794,000 121,516,000 143,447,000 162,730,000 191,060,000 248,973,000 262,136,000 278,903,000 283,254,000 306,306,000 294,801,000 313,310,000 339,907,000 223,345,000 241,511,000 259,247,000 268,045,000 282,977,202 142,418,089 156,020,828 169,303,445 112,313,122 122,774,619 134,284,191 98,118,606 109,127,019 117,205,921 124,454,324 133,744,497 139,654,016 144,707,127 138,347,415 71,225,193        
        accounts receivable from collaboration
      		       43,000 43,000  342,000 717,000 944,000         3,590,000 3,315,000 3,055,000 3,374,000 2,944,000 2,903,000 2,987,000 2,430,000 2,589,862 2,125,597 2,263,556 2,273,421 1,400,374                   
        deferred revenue - short-term
      		        30,915,000               6,715,000 6,411,000 6,151,000 6,082,000 9,933,000 5,100,000 5,105,104 5,512,109 5,159,587 5,229,227 4,995,894 4,995,894 4,995,894                 
        deferred revenue - long-term
      		        55,379,000            8,987,000 8,987,000  29,326,000 30,637,000 32,268,000 33,582,000 29,868,000 35,560,000 36,819,053 38,078,292 39,323,844 40,555,708 41,814,946 43,074,186 44,319,737                 
        deferred revenue
      		         2,733,000 2,733,000 2,733,000 2,733,000 2,733,000 2,733,000 2,733,000 2,733,000 2,733,000 8,987,000 8,987,000                                 
        marketable securities - short-term
      		            39,192,000 53,978,000 73,626,000 71,826,000 101,000,000 110,142,000                                   
        marketable securities - long-term
      		              11,908,000 23,459,000 27,972,000 9,180,000                                   
        accounts receivable from collaborations
      		             1,246,000 523,000 524,000 336,000 769,000 297,000 203,000 1,230,000                                
        indefinite-lived intangible asset
      		                 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000                        
        goodwill
      		                 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,000 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,638,136 12,737,350 12,737,350 12,142,702       
        deferred tax liabilities
      		                 2,531,000 2,531,000 2,531,000 2,531,000 2,531,000 2,531,000 2,531,000 2,531,000 3,251,000 3,252,000 3,252,000 3,252,000 2,107,300 2,108,367 2,135,802 2,135,802 11,146,312 11,176,072 11,119,651 11,119,651 11,600,000 11,600,000 11,600,000 11,600,000 11,600,000 11,600,000 11,600,000 11,600,000 12,142,702       
        accrued clinical expenses
      		                 3,744,000 3,676,000 4,342,000 4,444,000 4,451,000 4,362,000 4,633,000 4,826,000                            
        accumulated other comprehensive income
      		                      104,000                              
        operating lease right-of-use assets
      		                        11,975,000 12,783,000 12,672,000 13,063,000                         
        deferred rent
      		                            108,000 7,903                       
        accrued expenses
      		                         9,430,000 7,585,000 10,141,000 9,679,000 6,517,053 5,079,780 4,647,472 6,139,000 6,352,512 6,305,547 4,013,562 4,752,823 3,644,282 2,630,946 1,243,194 2,039,204 1,187,230 935,665 877,540 146,420  48,435 37,415     
        ​
      		                          2,019,000                          
        collaboration revenue
      		                          3,080,000                          
        operating expenses:
      		                                                    
        research and development
      		                          18,700,000                          
        general and administrative
      		                          4,080,000                          
        total operating expenses
      		                          22,780,000                          
        income from operations
      		                          -19,700,000                          
        other income
      		                          4,000                          
        interest and other income
      		                          1,182,000                          
        total other income
      		                          1,186,000                          
        income before income taxes
      		                          -18,514,000                          
        income tax benefit
      		                          11,000                          
        net income
      		                          -18,503,000                          
        other comprehensive income
      		                                                    
        unrealized gain on marketable securities, net of tax
      		                          52,000                          
        comprehensive loss
      		                          -18,451,000                          
        net income per share
      		                          -720                          
        weighted-average common shares outstanding, basic and diluted
      		                          25,740,500,000                          
        marketable securities, at fair value
      		                            176,609,000 114,187,793 38,480,105 42,232,348 37,914,482 39,052,821 36,123,684 20,105,000 24,388,403 34,851,387 43,205,005 37,928,473 40,556,652            
        long-term assets
      		                                                    
        property, plant and equipment
      		                            557,000 515,798 639,897 731,500 860,026 593,126 131,857 182,771 214,687 128,453 113,679 132,214 148,609 156,483 174,035 173,248 156,441        
        total long-term assets
      		                            45,543,000 43,104,449 44,888,871 42,795,228 46,184,933 43,661,361 45,106,083 42,062,507 44,543,942 49,872,193 53,102,934 65,365,125 65,376,032 73,150,852 73,374,372          
        long-term liabilities
      		                                                    
        total long-term liabilities
      		                            38,920,000 38,934,256 40,186,659 41,459,646 42,691,510 52,961,258 54,250,258 55,439,388 11,119,651 11,600,000 11,600,000 11,600,000 11,600,000 11,600,000 11,600,000          
        security deposits
      		                             950,515 406,735 425,592 339,558 425,789 327,250 241,600 255,366 205,344 183,698 204,279 197,158 170,126 125,084 98,899 115,005        
        intangible assets
      		                             29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 29,000,000 30,137,350       
        accounts receivable
      		                                  1,113,759                  
        other current assets
      		                                     609,351 556,644 765,681 704,287 705,295 605,162 283,836 125,284 147,178 171,554 134,780 84,983 97,107 101,531 18,915 
        cash
      		                                           96,054,082 29,091,113       14,571,055 
        liabilities and stockholders' deficit
      		                                                    
        common stock issuable, 0 and 125,000 shares at december 31, 2014 and december 31, 2013
      		                                                    
        computer equipment
      		                                             34,084 7,399 7,632 9,215 10,212 11,209  
        accounts payable and accrued expenses
      		                                             1,049,019   1,183,442    
        stockholders' deficit
      		                                                    
        common stock issuable, 25,000 shares at at september 30, 2014 and december 31, 2013
      		                                             368,750       
        total stockholders' deficit
      		                                             47,202,220       
        total liabilities and stockholders' deficit
      		                                             60,393,941       
        current assets:
      		                                                    
        advances to assembly pharmaceuticals, inc
      		                                              259,921      
        liabilities and stockholders’ equity
      		                                                    
        current liabilities:
      		                                                    
        commitments
      		                                                    
        stockholders’ equity:
      		                                                    
        preferred stock, .001 par value...
      		                                               220     
        common stock, .001 par value...
      		                                              4,679 20,663 12,404 7,230 7,190 6,746 
        common stock issuable, 25,000 shares at june 30, 2014 and december 31, 2013
      		                                              368,750      
        total stockholders’ equity
      		                                              20,285,414 30,047,662 52,205,018 9,434,193 12,532,203 11,626,116 
        total liabilities and stockholders’ equity
      		                                              21,755,202 32,365,322 53,388,460 11,523,832 14,137,821 14,616,601 
        1
      		                                                    
        common stock issuable, 125,000 shares at september 30, 2013
      		                                               368,750     
        deficit accumulated during the development stage
      		                                               -105,676,239 -48,669,726 -42,868,345 -35,906,832 -33,184,354 
        deferred financing and offering costs
      		                                                 47,978   
        borrowings under line of credit
      		                                                    
        term note – bank
      		                                                    
        interest payable – paramount credit partners, llc
      		                                                 148,210 187,536  
        notes payable - paramount credit partners, llc
      		                                                 1,319,698 1,295,186 1,270,673 
        term note - bank
      		                                                   800,000 
        deferred financing costs
      		                                                  24,557 26,631 
        computer equipment, net of accumulated depreciation of 27,260 and 14,734
      		                                                    
        borrowings under short-term note and line of credit
      		                                                   419,380 
        license fees
      		                                                    
        other
      		                                                    
        2007 senior convertible notes
      		                                                    
        interest payable – 2007 senior convertible notes
      		                                                    
        notes payable – paramount biosciences, llc
      		                                                    
        interest payable – paramount biosciences, llc
      		                                                    
        interest payable – related party
      		                                                   187,536 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 
                                                                    
          cash flows from operating activities
        		                                                            
          net loss
        		22,090,000 -9,196,000 -10,198,000 -8,818,000 -10,335,000 -9,613,000 -11,152,000 -9,077,000 -10,962,000 -14,420,000 -16,896,000 -18,950,000 -22,395,000 -23,145,000 -24,461,000 -23,091,000 -60,257,000 -18,803,000 -23,595,000 -27,200,000 -39,418,000 -3,349,000 7,270,000 -26,655,000 -27,084,000 -24,995,000 -18,503,000 -27,052,000 -26,160,971 -21,535,038 -26,806,232 -16,248,759 -3,007,072 -12,272,019 -13,598,864 -13,930,593 -11,546,687 -11,574,117 -10,152,200 -10,988,558 -7,748,276 -6,617,933 -6,942,671 -7,144,953 -6,229,351 -11,020,258 -2,469,273 -4,069,917 -6,047,034 -4,881,742 -4,751,888 -3,723,095 -3,791,109 -5,355,397 -7,470,048 -8,173,876 -18,859,358 -5,801,381 -6,961,513 -2,722,478 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                                            
          depreciation and amortization
        		32,000 32,000 32,000 33,000 32,000 33,000 32,000 32,000 84,000 116,000 126,000 124,000 124,000 134,000 120,000 120,000 120,000 119,000 120,000 107,000 314,000 140,000 122,000 115,000 117,000 117,000 125,000 135,000 169,570 161,484 143,860 168,086 94,549 41,846 50,914 31,916 25,001 18,157 18,535 18,558 17,040 17,552 16,493 13,904 7,080                
          stock-based compensation
        		1,461,000 1,670,000 834,000 712,000 751,000 797,000 833,000 739,000 959,000 1,135,000 1,190,000 1,835,000 2,013,000 1,556,000 1,581,000 1,443,000 1,945,000 1,592,000 1,986,000 -286,000 3,747,000 6,048,000 7,134,000 4,924,000 6,509,000 5,404,000 2,068,000 6,577,000 6,807,490 6,005,772 11,588,971 4,082,767 2,768,432 2,597,102 2,011,261 1,224,647 991,476 1,055,043 1,518,138 1,459,855 1,521,131 1,149,429 2,620,244 2,585,780 2,635,461 7,435,698 312,522 253,813 254,418 442,796 711,559 268,016 589,992 701,106 826,198 714,355    1,152,786 
          net accretion of investments in marketable debt securities
        		-828,000 -631,000 -379,000 -508,000 -593,000 -841,000 -960,000 -1,264,000                                                     
          non-cash rent expense
        		204,000 209,000 219,000 219,000 353,000 351,000 354,000 359,000 982,000 816,000 854,000 855,000 861,000 860,000 891,000 893,000 900,000 903,000 902,000 1,135,000 1,751,000 1,155,000 1,157,000 1,151,000 1,110,000 1,136,000 1,117,000 1,091,000                                 
          realized gain on investments in marketable debt securities
        		                                                            
          changes in operating assets and liabilities:
        		                                                            
          accounts receivable from collaboration
        		-62,000    0 0   -43,000 342,000 375,000 227,000 302,000 -723,000 1,000 -188,000 433,000 -472,000 -94,000 1,027,000  -275,000 -260,000 319,000 -430,000 -41,000 84,000 -557,000 160,441 -464,265 137,959 9,865 -873,047                            
          prepaid expenses and other current assets
        		-2,126,000 -856,000 2,012,000 -1,075,000 -165,000 453,000 437,000 -652,000 -35,000 446,000 2,103,000 -1,598,000 -732,000 1,901,000 171,000 -12,000 807,000 -364,000 363,000 303,000 -1,994,000 203,000 -491,000 795,000 78,000 1,305,000 -2,510,000 -2,558,000 1,351,359 -611,374 -928,319 -905,666 53,934 27,022 320,317 -687,497                         
          accounts payable
        		-512,000 940,000 -132,000 290,000 -750,000 534,000 74,000 266,000 -297,000 -146,000 -320,000 -1,269,000 551,000 -512,000 1,047,000 -1,252,000 31,000 -238,000 -696,000 -1,036,000 2,987,000 -636,000 143,000 373,000 -978,000 -705,000 987,000 -1,266,000 705,374 448,589 166,102 248,935 1,253,332 182,699 -1,259,275 -420,948 -1,469,833 1,424,042 87,774 962,450 -100,641 160,044 113,452 283,242                 
          accrued research and development expenses
        		-671,000 1,367,000 -415,000 -167,000 687,000 -945,000 472,000 1,174,000 -734,000 -418,000 -1,009,000 -76,000 -1,340,000 16,000 850,000 196,000                                             
          other accrued expenses
        		2,021,000 2,321,000 1,105,000 -4,560,000 2,097,000 1,178,000 1,536,000 -3,693,000 1,858,000 -302,000 1,034,000 -4,161,000 1,640,000 950,000 2,233,000 -4,365,000 1,420,000 1,159,000 663,000 -8,312,000 4,708,000 1,539,000 1,392,000 -3,808,000                                     
          deferred revenue from a related party
        		-7,174,000 -9,877,000 -9,626,000 -9,419,000  -6,845,000 -8,533,000 -5,785,000                                                     
          operating lease liabilities
        		-195,000 -200,000 -210,000 -146,000 -353,000 -346,000 -238,000 -463,000 -1,054,000 -884,000 -918,000 -918,000 -923,000 -901,000 -923,000 -923,000 -930,000 -912,000 -903,000 -1,041,000 -1,131,000 -1,135,000 -1,127,000 -1,120,000 -1,081,000 -1,089,000 -1,062,000 -1,037,000                                 
          net cash from operating activities
        		14,237,000 -15,133,000 -16,758,000 -23,439,000 -407,000 -15,244,000 -17,102,000 -18,364,000 73,647,000 -13,848,000 -13,628,000 -23,428,000 -19,254,000 -19,822,000 -17,885,000 -27,502,000 -19,362,000 -18,882,000 -21,808,000 -33,344,000 -25,269,000 10,646,000 -23,116,000 -25,218,000 -20,528,000 -18,595,000 -21,005,000 -23,939,000 -16,726,829 -16,684,152 -16,046,197 -15,500,822 -9,770,063 -10,957,614 -12,357,151 34,944,909 -11,039,235 -7,864,320 -6,767,707 -9,210,393 -5,455,200 -5,186,127 -4,382,654 -3,673,353 -3,592,920 -3,875,127 -2,320,394 -5,185,061 -5,392,432 -4,655,102 -3,378,435 -4,370,119 -3,070,859 -5,283,801 -6,935,579 -6,089,551 -16,332,577 -4,069,320 -2,851,968 -1,814,967 
          capital expenditures
        		-24,000 0 0  0 0 -14,000 -14,000 -71,000 -136,000 0 0 0 0 0  -18,000 0 0 -3,078,000 0 0 -405,000 -65,000 -15,000 0 -51,000 -1,488,000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
          free cash flows
        		14,213,000 -15,133,000 -16,758,000  -407,000 -15,244,000 -17,116,000 -18,378,000 73,576,000 -13,984,000 -13,628,000 -23,428,000 -19,254,000 -19,822,000 -17,885,000  -19,380,000 -18,882,000 -21,808,000 -36,422,000 -25,269,000 10,646,000 -23,521,000 -25,283,000 -20,543,000 -18,595,000 -21,056,000 -25,427,000 -16,726,829 -16,684,152 -16,046,197 -15,500,822 -9,770,063 -10,957,614 -12,357,151 34,944,909 -11,039,235 -7,864,320 -6,767,707 -9,210,393 -5,455,200 -5,186,127 -4,382,654 -3,673,353 -3,592,920 -3,875,127 -2,320,394 -5,185,061 -5,392,432 -4,655,102 -3,378,435 -4,370,119 -3,070,859 -5,283,801 -6,935,579 -6,089,551 -16,332,577 -4,069,320 -2,851,968 -1,814,967 
          cash flows from investing activities
        		                                                            
          proceeds from maturities of marketable securities
        		32,800,000 22,700,000 34,500,000 26,432,000 34,200,000 39,200,000 36,300,000 21,000,000 18,700,000 21,670,000 14,645,000 10,000,000 22,000,000 19,500,000 16,500,000 30,000,000 43,000,000 33,250,000 32,500,000 66,450,000 56,365,000 46,000,000 64,252,000 55,000,000 37,000,000 35,320,000 70,138,000 61,453,000                                 
          purchases of marketable securities
        		-11,553,000 -180,929,000 -17,506,000 -19,846,000 -40,896,000 -14,712,000 -31,179,000 -3,714,000 -108,307,000 -2,653,000   -8,763,000 -2,966,000 -11,903,000 -3,951,000 -52,966,000 -22,680,000 -35,587,000 -49,213,000 -40,166,000 -108,782,000 2,000 -44,242,000 -132,007,000 -55,660,000 -44,637,000 -49,030,000 -68,911,186 -82,862,836 -19,135,350 -13,031,628 -8,212,070 -7,431,220   -1 1 0 -7,951,257 -6,112,640 -14,887,752                   
          purchases of property and equipment
        		-24,000    0 0 -14,000 -14,000 -71,000 -136,000   0    -18,000 0 0 -3,078,000 0 0 -405,000 -65,000 -15,000 0 -51,000 -1,488,000                                 
          net cash from investing activities
        		21,223,000 -158,271,000 16,994,000 6,586,000 -6,696,000 24,488,000 5,107,000 17,272,000 -89,654,000 18,881,000 -8,365,000 10,000,000 16,562,000 31,432,000 9,597,000 33,049,000 -8,484,000 20,070,000 -3,087,000 18,016,000 20,715,000 -49,887,000 76,549,000 20,693,000 -95,022,000 7,819,000 25,450,000 11,435,000 -62,158,822 -73,600,383 1,462,393 -1,100,188 -1,673,520 -1,510,769 -19,116,164 6,658,000 15,667,592 11,317,070 6,714,000 2,497,912 -3,838,761 -12,187,974 -48,798,064 -30,711 -211,436 491,426 0 -2,589 -1,311 0    0       
          cash flows from financing activities
        		                                                            
          proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs
        		0                                                            
          proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs
        		0                                                            
          proceeds from the exercise of warrants
        		0                                                            
          proceeds from the issuance of common stock under atm equity offering program, net of issuance costs
        		0 0 0 1,922,000     0 0 54,000 4,492,000                                                 
          proceeds from the issuance of common stock under espp
        		368,000 0   95,000 0   49,000 0   112,000 0                                               
          proceeds from the exercise of stock options
        		88,000    1,000 0               22,000 843,000 483,000 119,000    140,000 197,286 418,978 1,849,305 1,494,431 1,382,206 262,878 108,041 640,017        167,040                 
          proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs
        		                                                            
          net cash from financing activities
        		456,000 171,932,000 357,000 1,922,000 16,995,000 0   9,192,000 0 134,000 4,492,000 437,000 0   2,713,000 10,055,000 6,159,000 34,137,000 5,687,000 843,000 950,000 119,000 137,415,000 1,385,000 706,000 140,000 604,521 155,844,743 1,849,305 1,494,431 66,229,560 262,878 108,041 640,017     0 257,443 10,644,781 70,667,033 14,962,842 0 0 1,763,104 232,101 3,388,095 0 20,754,418 0 0 4,716,088 180,728 13,749 45,995,047 219,980 1,256,399 
          net increase in cash and cash equivalents
        		35,916,000    9,892,000    -6,815,000   -8,936,000 -2,255,000 11,610,000 -8,111,000 5,547,000 -25,133,000 11,243,000 -18,736,000 18,809,000 1,133,000 -38,398,000   21,865,000    -78,281,130 65,560,208 -12,734,499 -15,106,579   -31,365,274 42,242,926 4,780,997 3,452,750 -53,707 -6,712,481       -2,320,394 -3,424,546 -5,161,642 -1,267,007 -3,383,601 16,384,299 -3,070,860 -5,283,801 -2,222,731 -5,908,823 -16,318,828 41,925,727   
          cash and cash equivalents at the beginning of the year
        		                                                            
          cash and cash equivalents at the end of the year
        		                                                            
          supplemental non-cash investing and financing activities
        		                                                            
          operating lease liabilities arising from obtaining rou assets
        		            0 0   0 0 84,000 42,000  518,000 183,000 362,000                                     
          cash and cash equivalents at the beginning of the period
        		 0 0 38,344,000  0 0 19,841,000 0 0 0 52,418,000 0 0 0 45,627,000 0 0 0 59,444,000 0 0 0 46,732,000 0 0 0 41,471,000 -209 0 0 82,033,209 0 0 0 28,575,085 0 0 0 27,107,526                     
          cash and cash equivalents at the end of the period
        		 -1,472,000 593,000 23,413,000  9,244,000 459,000 18,749,000 -6,815,000 5,033,000 -21,859,000 43,482,000 -2,255,000 11,610,000 -8,111,000 51,174,000 -25,133,000 11,243,000 -18,736,000 78,253,000 1,133,000 -38,398,000 54,383,000 42,326,000 21,865,000 -9,391,000 5,151,000 29,107,000 -78,281,339 65,560,208 -12,734,499 66,926,630 54,785,977 -12,205,505 -31,365,274 70,818,011 4,780,997 3,452,750 -53,707 20,395,045                     
          net decrease in cash and cash equivalents
        		  593,000 -14,931,000   459,000 -1,092,000                -4,406,000   5,151,000 -12,364,000                                 
          loss on disposal of property and equipment
        		                                                            
          other assets
        		        240,000 -220,000 2,000 555,000 724,000 22,000 540,000 -472,000 219,000 4,171,000 -59,000 358,000 -412,000 -2,141,000 -2,178,000 23,000 -13,000 22,000 -32,000 1,687,000            -7,121    16,106                 
          deferred revenue
        		                0    0 8,987,000 -36,041,000 -1,007,000 -1,371,000 -1,245,000 -137,000 -859,000 -1,264,222 -1,666,244 -893,030 -1,301,504 -1,025,905 -1,259,240 -1,245,551 49,315,631                         
          proceeds from sale of property and equipment
        		                0 0 0 857,000                                         
          proceeds from the issuance of common stock under atm equity offering programs, net of issuance costs
        		                                                            
          supplemental disclosure of cash flow information
        		                                                            
          income taxes paid
        		                                                            
          proceeds from the issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs
        		     0                                                       
          net amortization of investments in marketable debt securities
        		        -1,051,000 -313,000 -169,000 -52,000 -79,000 20,000 65,000 149,000                                             
          proceeds from sale of marketable securities
        		            1,825,000 15,000,000 5,000,000 7,000,000 0 9,500,000 0 3,000,000 6,266,000 12,895,000 12,700,000 10,000,000 0 28,159,000 0 500,000                                 
          proceeds from the sale of microbiome assets
        		                                                            
          proceeds from the issuance of common stock to a related party, net of issuance costs
        		                                                            
          impairment of goodwill and indefinite-lived intangible asset
        		                                                            
          deferred income tax benefit
        		                         8,000 -11,000 -7,000  -6,542   -8,944,833 -35,903                           
          gain on the sale of microbiome assets
        		                                                            
          remeasurement of lease liabilities arising from modification of rou assets
        		                0 0 0 -788,000                                         
          receivable from sale of microbiome assets included in prepaid expenses and other current assets
        		                                                            
          non-cash in-process research and development (ipr&d) expense
        		                                                            
          net accretion and amortization of investments in marketable debt securities
        		                188,000 149,000 157,000 92,000  21,000                                       
          purchase of ipr&d from an acquisition of assets
        		                                                            
          loss on disposal of fixed assets
        		                 0 14,000 1,611,000     0 0 0 102,000                                 
          accrued clinical expenses
        		                 68,000 -666,000 -102,000 -7,000 89,000 -271,000 -193,000                                     
          proceeds from the issuance of common stock under employee stock purchase plan
        		                 0    0                                       
          proceeds from sale of common stock, net of issuance costs
        		                 10,055,000 6,015,000 34,137,000                                         
          non-cash ipr&d expense
        		                                                            
          net accretion and amortization of investments in marketable securities
        		                       -135,000 -232,000 -362,000 -549,000 -592,000                                 
          deferred income tax expense
        		                                                            
          other
        		                        0 0 -4,000 -1,000                                 
          accounts receivable from collaborations
        		                                                            
          deferred rent
        		                            100,097                                
          purchase of ipr&d
        		                                                            
          proceeds from common stock and pre-funded warrants sold, net of underwriters' discount, commissions and costs
        		                                                            
          operating lease liabilities arising from obtaining right-of-use assets
        		                                                            
          proceeds from common stock and pre-funded warrants sold, net of underwriters' discount and costs
        		                                                            
          accrued expenses
        		                         1,850,000 -2,578,000 398,000 3,122,947 1,437,273 432,308 -1,491,528 -213,512 46,965 2,291,985 -739,261 1,108,541 1,013,336 1,387,752 -796,010 828,820 251,565 157,339 731,120                 
          proceeds from common stock sold, net of underwriters' discount and cost
        		                                                            
          net proceeds from the issuance of common stock through equity plans
        		                                                            
          net proceeds from issuance of common stock through equity plans
        		                                                            
          amortization of discount on marketable securities
        		                                                            
          realized loss from marketable securities
        		                              127,234 23,016 37,828 99,068 340,984 137,248 521,786 273,572 142,676 201,827                     
          deferred income tax expenses
        		                                                            
          purchases of fixed assets
        		                            -210,798 -37,385 -52,257 -39,560     -111,235 -32,931 0 -2,163                     
          redemptions of marketable securities
        		                            6,963,162 9,299,838 20,650,000 11,971,000 6,899,999 6,423,566 13,475,000 6,658,000 15,778,828 11,350,000 6,714,000 10,451,332                     
          proceeds from common stock sold, net of underwriters' discounts and cost
        		                            -765            0 0                   
          proceeds from issuance of common stock under espp
        		                                                            
          amortization of premium (discount) on investment securities
        		                                                            
          security deposits
        		                             -543,780 18,857 -86,034 86,231 -98,539 -85,650 13,766 -50,022 -21,646   -27,032 -45,042                   
          supplemental disclosure of cash flow information:
        		                                                            
          shares issued for option exercise - receivable
        		                                                            
          change in unrealized gain on marketable securities available-for-sale, before tax expense
        		                             22,657   -69,679 16,021                           
          change in unrealized gain on marketable securities available-for-sale
        		                               -66,959    76,092    72,090                     
          loss on sale of fixed assets
        		                                                            
          sale of fixed assets
        		                                                            
          cashless exercise of warrants
        		                                        0 0                   
          supplemental disclosure of non-cash activities:
        		                                                            
          assembly business combination
        		                                                            
          goodwill
        		                                                            
          accounts payable and accrued expenses
        		                                            3,337,261 -1,294,882 7,339 -1,175,605 320,394 -267,723 608,740 -768,815 64,262 -710,642 -461,020 1,339,784 1,329,632 438,994 434,015 -189,999 
          cash acquired in business combination
        		                                            0                
          purchases of fixed assets and construction in progress
        		                                                            
          accounts receivable
        		                                                            
          issuance of warrants for services
        		                                            0                
          security deposits collected
        		                                                            
          proceeds from exercise of stock options
        		                                        0 257,443                   
          issuance of common stock in exchange for restricted stock units
        		                                                            
          conversion of preferred stock to common stock
        		                                                            
          other current assets
        		                                     -52,707 209,037 -61,394 24,162 -100,133 -321,326 -158,552 -11,112 324,443 -172,281 -195,522 71,108 42,743 46,127 -164,066 51,600 45,901 101,368 -196,324 22,854 12,124 4,426 -82,618 
          equipment
        		                                                            
          intangible assets
        		                                                            
          share exchange - business combination
        		                                                            
          fair value of vested options and restricted stock units - in connection with business combination
        		                                                            
          deferred tax liability
        		                                                            
          change in unrealized loss on marketable securities available-for-sale
        		                                     2,794   1,209,463 -253,659                   
          accrued offering cost related to the issuance of common stock
        		                                           -60,000                 
          purchase of fixed assets
        		                                        -10,270 0 -17,280 -30,711 -129,437                
          redemption of marketable securities
        		                                        2,283,999                    
          cash and cash equivalents at beginning of year
        		                                                            
          cash and cash equivalents at end of year
        		                                                            
          realized gain from marketable securities
        		                                                            
          net increase in cash
        		                                         -17,116,658 -42,535,937 66,962,969 11,158,486               -570,531 
          cash and cash equivalents at beginning of period
        		                                         0                   
          cash and cash equivalents at end of period
        		                                         -17,116,658                   
          changes in assets and liabilities:
        		                                                            
          proceeds from issuance of common stock, net of cost
        		                                           70,499,993                 
          cash at the beginning of the period
        		                                           29,091,113 0                
          cash at the end of the period
        		                                           96,054,082 11,158,486                
          supplemental schedule of non-cash financing activities
        		                                                            
          fair value of vested options and restricted stock units assumed - in connection with
        		                                                            
          business combination
        		                                                            
          proceeds from issuance of common stock
        		                                                            
          cash flows from operating activities:
        		                                                            
          stock-based payments to consultants
        		                                              273 904 6,841 7,127 5,616 16,574      391,432   
          depreciation
        		                                              1,026 1,266 1,841 1,697 1,411 1,267 1,267 1,268 1,086 997 997 997 997 755 
          cash flows from investing activities:
        		                                                            
          purchase of office and computer equipment
        		                                              0 -2,589 -1,311 0   -1 0     -1 -11,963 
          cash flows from financing activities:
        		                                                            
          net proceeds from sale of common and preferred stock
        		                                              0 1,763,104  3,388,095 0 20,754,418         
          beginning of period
        		                                              0 27,061,268 0 0 0 20,489,219 0 0 0 36,975,434 0 0 0 14,571,055 
          end of period
        		                                              -2,320,394 23,636,722 -5,161,642 -1,267,007 -3,383,601 36,873,518 -3,070,860 -5,283,801 -2,222,731 31,066,611 -16,318,828 41,925,727 -2,631,989 14,000,524 
          stock issued in connection with license agreement
        		                                                            
          charge resulting from beneficial note conversion
        		                                                            
          stock issued to vendor
        		                                                            
          warrants issued in connection with related party note conversion
        		                                                            
          amortization of deferred financing costs and debt discount
        		                                                        0 279,933 22,438 26,587 
          non-cash research and development
        		                                                            
          interest payable - notes
        		                                                            
          expenses paid on behalf of the company satisfied through the issuance of notes
        		                                                            
          interest payable - related parties
        		                                                            
          proceeds from notes payable
        		                                                            
          proceeds from notes payable to related parties
        		                                                            
          payment for deferred financing costs
        		                                                            
          repayment of notes
        		                                                            
          repayment of notes payable - related party
        		                                                            
          proceeds from the exercise of warrants and options
        		                                                     0       
          supplemental schedule of non-cash financing activities:
        		                                                            
          warrants issued to placement agent
        		                                                            
          warrants issued to investors in connection with convertible notes
        		                                                            
          debt discount on paramount credit partners, llc notes
        		                                                            
          related party notes and accrued interest converted to 2010 senior convertible notes
        		                                                            
          debt discount on 2010 senior convertible notes
        		                                                            
          notes and accrued interest converted to common stock
        		                                                            
          supplemental disclosure - cash paid for interest
        		                                                            
          charge resulting from beneficial conversion feature
        		                                                            
          interest payable - 2007 senior convertible notes
        		                                                            
          interest payable - 2010 senior convertible notes
        		                                                            
          interest payable - paramount credit partners, llc
        		                                                            
          prepaid research and development
        		                                                            
          net proceeds from initial public offering and other offerings
        		                                                            
          proceeds from private placement
        		                                                            
          proceeds from exercise of warrants and options
        		                                                            
          proceeds from 2010 senior convertible notes
        		                                                            
          proceeds from notes payable to paramount credit partners, llc
        		                                                            
          repayment of paramount credit partners, llc note
        		                                                            
          proceeds from 2007 senior convertible notes
        		                                                            
          proceeds from utilization of short-term note and line of credit
        		                                                            
          repayment of debt facilities
        		                                                          0 -419,380 
          proceeds from term note payable
        		                                                            
          repayment of term note payable
        		                                                            
          proceeds from receipt of subscriptions
        		                                                            
          adjustments to reconcile net loss to net cash used in operating activities:
        		                                                            
          interest payable – notes
        		                                                            
          interest payable – related parties
        		                                                            
          supplemental disclosure – cash paid for interest
        		                                                         156,086 81,913 39,325 
          stock - based payments to consultants
        		                                                            
          cash flows from investing activities: - sum
        		                                                            
          net proceeds from sale of common stock
        		                                                     0       
          stock -based payments to consultants
        		                                                      66,837 225,513     
          proceeds from notes
        		                                                            
          interest payable – 2007 senior convertible notes
        		                                                            
          interest payable – 2010 senior convertible notes
        		                                                            
          net proceeds from ipo and the over-allotment option exercise
        		                                                         1 0 2,420,775 
          proceeds from utilization of line of credit
        		                                                            
          repayment of term note
        		                                                         0 0 -800,000 
          repayment of paramount credit partner notes
        		                                                            
          repayment of line of credit
        		                                                            
          proceeds from exercise of options and warrants
        		                                                       238,617     
          payment for shelf registration statement costs
        		                                                       -57,889     
          interest payable – paramount credit partners, llc
        		                                                            
          proceeds from exercise of warrants
        		                                                        13,749 -1 219,980 55,004 
          repayment of notes payable – related party
        		                                                            
          stock-based compensation to employees and directors
        		                                                         612,727   
          purchase of computer equipment
        		                                                            
          net proceeds from july 2011 public offering
        		                                                            
          repayment of paramount credit partners note
        		                                                            
          net proceeds from ipo